An estrogen response-related signature predicts response to immunotherapy in melanoma

An estrogen response-related signature predicts response to immunotherapy in melanoma

BackgroundEstrogen/estrogen receptor signaling influences the tumor microenvironment and affects the efficacy of immunotherapy in some tumors, including melanoma. This study aimed to construct an estrogen response-related gene signature for predicting response to immunotherapy in melanoma.MethodsRNA...

Full description

Bibliographic Details
Main Authors:	Min Lin, Tian Du, Xiaofeng Tang, Ying Liao, Lan Cao, Yafang Zhang, Wei Zheng, Jianhua Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	melanoma immune checkpoint blockade gene signature estrogen tumor-infiltrating lymphocyte
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1109300/full

Similar Items

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
by: Timothy V. Pham, et al.
Published: (2020-08-01)

The age of enlightenment in melanoma immunotherapy
by: Mark R. Albertini
Published: (2018-08-01)

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
by: Emilie Picard, et al.
Published: (2020-03-01)

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study
by: Ryan C. Augustin, et al.
Published: (2023-06-01)

Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma
by: Sena Zeynep Usta, et al.
Published: (2023-12-01)

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
by: Nicholas D. Klemen, et al.
Published: (2019-07-01)

Immunotherapy in Melanoma: Recent Advances and Future Directions
by: Andrew Knight, et al.
Published: (2023-02-01)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
by: Devayani Machiraju, et al.
Published: (2021-01-01)

Estrogen Receptors and Melanoma: A Review
by: Emi Dika, et al.
Published: (2019-11-01)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
by: Teresa Kim, et al.
Published: (2014-12-01)

Natural Killer cell recognition of melanoma: new clues for a more effective immunotherapy
by: Raquel eTarazona, et al.
Published: (2016-01-01)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
by: Chune Yu, et al.
Published: (2019-05-01)

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
by: Hwa Kyung Byun, et al.
Published: (2021-05-01)

Ferroptosis-Related Gene Signature Predicts the Prognosis of Skin Cutaneous Melanoma and Response to Immunotherapy
by: Ziqian Xu, et al.
Published: (2021-11-01)

High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC
by: Michael S. Oh, et al.
Published: (2021-01-01)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
by: Robert A. Szczepaniak Sloane, et al.
Published: (2021-10-01)

ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors
by: Qiyi Yi, et al.
Published: (2022-12-01)

A 13-Gene Signature Based on Estrogen Response Pathway for Predicting Survival and Immune Responses of Patients With UCEC
by: Yimin Li, et al.
Published: (2022-04-01)

Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma
by: Yujian Xu, et al.
Published: (2022-07-01)

Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma
by: Weifeng Hong, et al.
Published: (2020-12-01)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
by: Marin A. McDonald, et al.
Published: (2018-05-01)

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
by: Mariana Aris, et al.
Published: (2017-08-01)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
by: Elena Shklovskaya, et al.
Published: (2022-10-01)

PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
by: Bruna Pereira Sorroche, et al.
Published: (2023-03-01)

Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in Melanoma
by: Nian Liu, et al.
Published: (2020-08-01)

Expression of Estrogen Receptor Alpha in Malignant Melanoma
by: Parvin Rajabi, et al.
Published: (2017-01-01)

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
by: George Georgoulias, et al.
Published: (2022-10-01)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
by: Anjali Rohatgi, et al.
Published: (2021-03-01)

Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma
by: Shuzhao Chen, et al.
Published: (2022-12-01)

Bilateral anterior uveitis after immunotherapy for malignant melanoma
by: Chia-Jui Chang, et al.
Published: (2018-01-01)

Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy
by: Felix Peisen, et al.
Published: (2022-06-01)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
by: Damian J. Ralser, et al.
Published: (2023-06-01)

Prognostic Value and Immunological Characteristics of a Novel RNA Binding Protein Signature in Cutaneous Melanoma
by: Jun Tian, et al.
Published: (2021-08-01)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
by: Nicholas J. Bevins, et al.
Published: (2022-11-01)

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
by: John E. Mullinax, et al.
Published: (2018-03-01)

Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
by: Andrea Gaißler, et al.
Published: (2022-07-01)

Identification and Validation of a Novel Immune-Related lncRNA Signature for Bladder Cancer
by: Shan Hua, et al.
Published: (2021-07-01)

A combined aging and immune prognostic signature predict prognosis and responsiveness to immunotherapy in melanoma
by: Wenchang Lv, et al.
Published: (2022-08-01)

Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma
by: Xue L, et al.
Published: (2021-10-01)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
by: Julie Vackova, et al.
Published: (2021-04-01)